Key result
Transplacental antiarrhythmics for fetal SVT require careful maternal monitoring due to potential adverse effects.
Why the study?
Antiarrhythmic medications for sustained fetal supraventricular tachycardia have the potential to cause significant adverse effects, prompting an examination of maternal safety during transplacental treatment.
What are the maternal safety considerations and monitoring practices during transplacental antiarrhythmic treatment for fetal supraventricular tachycardia?
Design
Narrative review
Authors
Loading...
Supports maternal monitoring protocols in fetal SVT therapy; leaves open prospective validation before practice change.
What are the maternal safety considerations and monitoring practices during transplacental antiarrhythmic treatment for fetal supraventricular tachycardia?
This review provides a suggested maternal monitoring protocol to optimize safety during transplacental antiarrhythmic therapy for fetal supraventricular tachycardia.
Malhamé et al. (2018) conducted a review in Fetal supraventricular tachycardia. Transplacental antiarrhythmic treatment (digoxin, flecainide, sotalol, amiodarone) was evaluated on Maternal safety and adverse reactions. Transplacental antiarrhythmic therapy for fetal supraventricular tachycardia requires careful maternal monitoring due to potential adverse effects, prompting a suggested safety protocol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: